- Home
- TRUP vs NAMS Comparison
TRUP vs NAMS Comparison
Compare TRUP & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUP
- NAMS
- Stock Information
- Founded
- TRUP 2000
- NAMS 2019
- Country
- TRUP United States
- NAMS Netherlands
- Employees
- TRUP N/A
- NAMS N/A
- Industry
- TRUP Medical Specialities
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- TRUP Health Care
- NAMS Health Care
- Exchange
- TRUP Nasdaq
- NAMS Nasdaq
- Market Cap
- TRUP 2.1B
- NAMS 2.5B
- IPO Year
- TRUP 2014
- NAMS N/A
- Fundamental
- Price
- TRUP $55.15
- NAMS $18.58
- Analyst Decision
- TRUP Buy
- NAMS Strong Buy
- Analyst Count
- TRUP 6
- NAMS 8
- Target Price
- TRUP $51.80
- NAMS $42.88
- AVG Volume (30 Days)
- TRUP 514.5K
- NAMS 1.0M
- Earning Date
- TRUP 08-07-2025
- NAMS 08-06-2025
- Dividend Yield
- TRUP N/A
- NAMS N/A
- EPS Growth
- TRUP N/A
- NAMS N/A
- EPS
- TRUP N/A
- NAMS N/A
- Revenue
- TRUP $1,321,538,000.00
- NAMS $47,140,000.00
- Revenue This Year
- TRUP $11.30
- NAMS N/A
- Revenue Next Year
- TRUP $6.01
- NAMS N/A
- P/E Ratio
- TRUP N/A
- NAMS N/A
- Revenue Growth
- TRUP 14.08
- NAMS 586.97
- 52 Week Low
- TRUP $26.96
- NAMS $14.06
- 52 Week High
- TRUP $57.90
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- TRUP 71.93
- NAMS 47.21
- Support Level
- TRUP $54.58
- NAMS $17.67
- Resistance Level
- TRUP $57.34
- NAMS $18.97
- Average True Range (ATR)
- TRUP 1.94
- NAMS 1.24
- MACD
- TRUP 0.20
- NAMS -0.14
- Stochastic Oscillator
- TRUP 86.50
- NAMS 20.45
About TRUP Trupanion Inc.
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue primarily from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.